With no approved pharmacotherapy for methamphetamine use disorder anywhere in the world, every credible clinical trial in this space carries outsized significance. Methamphetamine addiction drives enormous burdens of cardiovascular disease, psychosis, HIV transmission, and premature death — yet clinicians have had no FDA- or TGA-approved medication to offer. A rigorous Phase 3 result could fundamentally change that calculus.
This Australian Phase 3, double-blind, placebo-controlled trial enrolled 339 adults with moderate-to-severe methamphetamine use disorder across six outpatient clinics, randomizing them to mirtazapine 30 mg daily or matched placebo for 12 weeks. Participants were heavy users at baseline, reporting methamphetamine on a median of 24 out of 28 days. The primary endpoint was change in methamphetamine use days over the prior 28 days from baseline to week 12. Secondary outcomes encompassed depression severity, insomnia, HIV risk behavior, quality of life, and methamphetamine-negative oral fluid samples — a notably comprehensive outcome set that reflects both the pharmacological and harm-reduction dimensions of the disorder.
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) that antagonizes alpha-2 adrenergic receptors and multiple serotonin receptor subtypes. Its proposed mechanism in stimulant use disorder involves blunting the noradrenergic surge that underlies methamphetamine's reinforcing properties, while its sedating profile may also address the severe insomnia that frequently precipitates relapse. Earlier pilot data and a smaller Thai trial had generated cautious optimism, but real-world effectiveness in routine clinical settings — the explicit framing of this trial — remained unestablished.
The Phase 3 designation and multi-site outpatient setting give these findings considerably more translational weight than prior proof-of-concept work. Key limitations include the single-country sample, which may limit generalizability to populations with different use patterns or comorbidities, and the 12-week treatment window, which cannot speak to long-term durability. If the primary endpoint achieves significance, this trial may represent the most actionable advance in stimulant use disorder pharmacotherapy in decades — a potentially paradigm-shifting result for addiction medicine globally.